Expansion of Prediction Markets into Clinical Trial Outcomes Raises Regulatory and Ethical Concerns

Prediction platforms Kalshi and Polymarket have introduced wagering on FDA drug approval outcomes, with plans to extend betting to clinical trial results. This development faces scrutiny over potential impacts on research integrity, market manipulation, and the influence of financial incentives on medical data reporting.